(Q33875604)

29 July 2017

title

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model (English)

1 reference

29 July 2017

8

C M Croce

1 reference

29 July 2017

K A Beckwith

1

1 reference

29 July 2017

F W Frissora

2

1 reference

29 July 2017

M R Stefanovski

3

1 reference

29 July 2017

W H Towns

4

1 reference

29 July 2017

C Cheney

5

1 reference

29 July 2017

X Mo

6

1 reference

29 July 2017

J Deckert

7

1 reference

29 July 2017

J M Flynn

9

1 reference

29 July 2017

L A Andritsos

10

1 reference

29 July 2017

J A Jones

11

1 reference

29 July 2017

K J Maddocks

12

1 reference

29 July 2017

G Lozanski

13

1 reference

29 July 2017

J C Byrd

14

1 reference

29 July 2017

N Muthusamy

15

1 reference

29 July 2017

publication date

21 January 2014

1 reference

29 July 2017

1 reference

29 July 2017

volume

28

1 reference

29 July 2017

issue

7

1 reference

29 July 2017

page(s)

1501-1510

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2014.32

29 July 2017

exact match

0 references

cites work

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

The tetraspanin CD37 orchestrates the α(4)β(1) integrin-Akt signaling axis and supports long-lived plasma cell survival

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Trastuzumab emtansine for HER2-positive advanced breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Role of the microenvironment in chronic lymphocytic leukaemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090271

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

5 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.32

The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.32

Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.32

Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.32

Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.32

Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.32

Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles

21 January 2018

1 reference

12 December 2020

Action of novel CD37 antibodies on chronic lymphocytic leukemia cells

1 reference

12 December 2020

A unique antigen on mature B cells defined by a monoclonal antibody

1 reference

12 December 2020

A model for human B-chronic lymphocytic leukemia in human/mouse radiation chimera: evidence for tumor-mediated suppression of antibody production in low-stage disease

1 reference

12 December 2020

A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.32

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference